Please assess the completion status of the following clinical trial:

Trial Title: CP-690,550 and Midazolam Drug-Drug Interaction Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and/or female (non-child bearing potential) subjects~Exclusion Criteria:~* Clinically significant infections within the past 3 months~* History of previously untreated infection with Mycobacterium tuberculosis~* Positive screening test for hepatitis B surface antigen, anti-hepatitis C antibody, or human immunodeficiency virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Sequence 1 (Type: EXPERIMENTAL): None
- Treatment Sequence 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).